Wegovy's list price is $1,349.02 per package (a month's supply — one carton of pens, or one bottle of tablets). Very few people pay that. If you have commercial insurance that covers the drug, Novo Nordisk's savings card can bring the copay down to as little as $25 a month, capped at $100 of savings per month. If you are paying out of pocket, buying direct through NovoCare Pharmacy costs between $149 and $399 a month depending on which form and dose you are on. All three figures were checked on July 13, 2026 against Novo Nordisk's own pricing pages — this market has moved every few months for two years, so verify before you plan around any number, including ours.
The three numbers, and what each one is for
Most cost articles give you one number and it is usually the wrong one. There are really three, and which applies to you depends on one question: who is paying.
| Route | What you pay per month | Who it is for |
|---|---|---|
| List price | $1,349.02 per package | Nobody, in practice — it is the sticker before rebates, insurance and discounts. It matters only because it is what an uncovered claim gets measured against. |
| Commercial insurance + savings card | As little as $25; savings capped at $100/month | People with commercial (job-based or other private) drug coverage whose plan actually covers Wegovy. Government insurance excluded. |
| Cash / self-pay via NovoCare Pharmacy | Pill $149 (1.5 mg and 4 mg; the 4 mg rate runs only to Aug 31, 2026, then $199). Pen $199 for two monthly fills at 0.25 mg or 0.5 mg for people new to the offer, available through Dec 31, 2026, then $349. Wegovy HD 7.2 mg pen $399. | Uninsured people, and insured people whose plan excludes weight-management drugs — you can pay cash outside your insurance. |
| Medicare GLP-1 Bridge | $50, if you meet CMS clinical criteria | Eligible Medicare Part D enrollees. Runs July 1, 2026 – Dec 31, 2027. |
Two things about that cash column deserve emphasis, because they are the biggest change of the last eighteen months. First, the direct-from-manufacturer price is now roughly one-ninth to under one-third of list — a self-pay patient is no longer looking at $1,300 a month. Second, several of these prices are explicitly time-limited promotions with published end dates: the $199 pen rate covers two monthly fills and is offered through December 31, 2026, and the $149 rate on the 4 mg pill runs only until August 31, 2026. Novo reserves the right to change or end these programs. Check NovoCare the week you fill, not the month you read this.
"I have insurance" is not the same as "I'm covered"
This is the sentence most people wish someone had told them before they got excited at the pharmacy counter.
Employer health plans routinely carve weight-management drugs out of the benefit entirely. In KFF's 2025 Employer Health Benefits Survey, about 19% of firms with 200 or more workers covered GLP-1 drugs when used primarily for weight loss — 16% of firms with 200–999 workers, 30% of firms with 1,000–4,999 workers and 43% of firms with 5,000 or more. Among firms that did not cover them, 67% said they were "not likely" to start within the next twelve months. In other words, for most people with employer coverage, this drug simply is not in the benefit — and a benefit that does not exist is not a denial you can appeal on medical grounds. There is nothing to appeal to.
So the pharmacy rejection code you got may mean any of three completely different things, and they have different fixes:
- Not covered / benefit exclusion. Your plan does not pay for weight-loss drugs at all. Cash-pay through the manufacturer is usually the realistic route. Some people also have a covered-indication conversation with their prescriber (for example, semaglutide is approved under a different brand and label for type 2 diabetes) — that is a clinical decision your prescriber makes based on your actual diagnosis, not a workaround you construct. Never misrepresent your history to an insurer; it is fraud, and it can cost you the coverage you do have.
- Prior authorization required. Covered, but your plan wants documentation first — typically BMI, comorbidities, sometimes a documented lifestyle-intervention attempt. This is winnable. Your prescriber's office submits it.
- Step therapy. Covered, but only after you have tried something cheaper first. Also appealable, especially if you have already tried and failed that drug.
Call the member-services number on your card and ask, word for word: "Is Wegovy — semaglutide for weight management — on my formulary? If not, is that a formulary exclusion or a plan exclusion for the whole weight-management drug class? If it is covered, what tier, what is my copay, and is prior authorization or step therapy required?" Write down the date, the name of the person, and the reference number. Our cost and coverage estimator walks you through the same script.
Who the savings card excludes
The $25 copay card is a commercial-insurance instrument. Novo Nordisk's terms exclude people whose drug coverage comes from a government program — that means Medicare (including Part D), Medicaid, TRICARE, the VA, and other federal or state healthcare programs. If you are in one of those, the copay card is not available to you through your insurance, and no amount of arguing at the counter changes it: the restriction comes from federal anti-kickback law, not from Novo being difficult. What you can still do is buy outside your coverage at the cash price.
What Medicare beneficiaries do now have is separate and new. The Medicare GLP-1 Bridge, which opened July 1, 2026 and runs through December 31, 2027, sets a $50 monthly copay for eligible Part D enrollees, and all Wegovy formulations are included. CMS's clinical criteria are specific: BMI 35 or higher; or BMI 30 or higher with heart failure, uncontrolled hypertension or chronic kidney disease; or BMI 27 or higher with prediabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease. The criteria are assessed as of when GLP-1 therapy was started, which matters if you began treatment before July 2026 and have since lost weight. One catch worth knowing: because the program sits outside standard Part D coverage, those $50 payments do not count toward your Part D deductible or your annual out-of-pocket cap.
Medicaid is state-by-state. Some state programs cover anti-obesity medications; many do not. Your state's Medicaid preferred drug list is the only authority that matters, and it is public.
Routes to a lower cost — honestly rated
| Route | Realistic effect | The catch |
|---|---|---|
| Savings card on top of commercial coverage | Down to as little as $25/month | Savings capped at $100/month, so if your plan copay is $400 you still pay $300. Government insurance excluded. |
| NovoCare Pharmacy self-pay | $149–$399/month | Promotional tiers with published expiry dates (Aug 31, 2026 for the 4 mg pill rate; Dec 31, 2026 for the $199 pen rate). You are buying outside your insurance, so nothing counts toward your deductible. |
| Prior authorization / appeal | Can turn a $1,349 claim into a normal copay | Only works if the drug is on your formulary at all. Takes weeks. Requires your prescriber's office to do the paperwork. |
| Medicare GLP-1 Bridge | $50/month | Strict CMS clinical criteria; doesn't count toward the Part D deductible or out-of-pocket cap; time-limited through 2027. |
| HSA / FSA dollars | Pays with pre-tax money, so the effective discount is roughly your marginal tax rate | Doesn't lower the price, only your tax on it. Requires a prescription (it will have one). |
| Switching to a different GLP-1 | Sometimes large — plans cover different drugs | A clinical decision, not a shopping decision. See Zepbound vs Wegovy and Wegovy vs Ozempic before you raise it with your prescriber. |
| Compounded semaglutide | Often advertised far cheaper | Not FDA-approved, and the legal ground has shifted — see below. Not a straightforward cheaper version of the same thing. |
The compounded question, briefly
Start with the fact that gets skipped in the ads: compounded semaglutide is not an FDA-approved product. FDA does not review compounded drugs for safety, effectiveness or manufacturing quality, which is a different thing from saying they are all bad — it means the assurance you get with an approved product is simply not there.
During the 2023–2025 shortage, compounding pharmacies were permitted to make semaglutide because approved supply could not meet demand. FDA declared the semaglutide shortage resolved on February 21, 2025, and the enforcement-discretion windows closed shortly after — April 22, 2025 for 503A compounding pharmacies, May 22, 2025 for 503B outsourcing facilities. With the drug commercially available again, compounders generally may not produce what is "essentially a copy" of it. Narrow exceptions remain for genuinely individualized preparations.
Anything still being marketed to you at $99 a month as "generic Wegovy" or "semaglutide, same molecule" deserves hard questions about what exactly it is, who made it, and under what authority. We are not telling you to use or avoid compounded product — that is a decision for you and a clinician. We are telling you the regulatory picture changed, and any page that quotes you a compounded price without saying so is selling, not informing. Read our explainer on how GLP-1 medications work and take the specifics to a prescriber.
A cheap source that is not a legitimate pharmacy is not a saving. A pharmacy that will sell you an injectable prescription drug without a prescription, without a licensed prescriber's involvement, or from an overseas website with no verifiable licensure, is not a bargain — it is an unknown vial. Price is one input. It is not the only one.
Dose and price are linked — but do not act on that yourself
Cash pricing varies by form and dose, which gives people the idea that they can save money by stretching a pen, splitting a dose, skipping a week, or doubling up after a missed one. So here is what the FDA label actually publishes — as information, not as instruction.
For the injection, the label sets a fixed escalation: 0.25 mg once weekly for weeks 1–4, then 0.5 mg for weeks 5–8, 1 mg for weeks 9–12, 1.7 mg for weeks 13–16, and 2.4 mg once weekly as the recommended maintenance dose, with 1.7 mg as an alternative maintenance dose. The label also describes a maximum of 7.2 mg once weekly (the Wegovy HD pen) for adults who have tolerated 2.4 mg for at least four weeks and for whom additional weight reduction is clinically indicated. The tablet has its own separate escalation — 1.5 mg, then 4 mg, then 9 mg, then 25 mg once daily as maintenance. On missed doses, the label says that if one injection is missed and the next scheduled dose is more than two days away, it can be given as soon as possible; if the next dose is less than two days away, the missed dose is skipped and dosing resumes on the regular day; and if two or more consecutive doses are missed, dosing is resumed as scheduled or, if needed, treatment is reinitiated following the escalation schedule. That is what the label says. Your prescriber sets your dose.
Do not self-adjust. Do not double up after a missed dose. Under-dosing to make a pen last blunts the drug's effect and can worsen side effects when you resume; improvising with the device introduces dosing errors. If cost is driving what you are considering doing with your medication, that is exactly the thing to tell your prescriber — out loud, in plain words. It is a clinical fact about your treatment, not an embarrassment.
When to talk to your prescriber
Book a conversation — don't just absorb the price — if any of these apply:
- You are rationing. Skipping, stretching or splitting doses because of cost. Say so directly. There may be a covered alternative, a patient-assistance route, or a different plan-year strategy.
- You were denied. Ask the office to pull the denial reason. "Not on formulary" and "prior authorization not submitted" are different problems with different fixes.
- Your out-of-pocket cost changed mid-year. Formularies change on January 1 and sometimes mid-year. A drug that cost $25 in March can cost $400 in July.
- You are considering a compounded product. Bring the actual product name, the pharmacy, and its licensure. Let a clinician look at it with you.
- You have persistent vomiting, severe abdominal pain, signs of gallbladder problems, or symptoms of pancreatitis. That is a call today, not a cost conversation.
If you are trying to work out whether a telehealth service is worth using for this, judge it on structure, not on advertising: does a licensed clinician in your state actually evaluate you, do they take a real history, do they send the prescription to a pharmacy you can name and look up, is the total cost (visit fee + drug + refills) disclosed before you pay, and can you reach a human if you have side effects? Our guide to evaluating online GLP-1 care lays out the checklist. We name no provider as a recommendation here, and we never will on a page about price.
Disclosure: VidaBeacon may earn a commission from some links in our product roundups and care-finder pages. That never changes what we publish about price, coverage or safety, and no company paid for a placement on this page.
Related: Wegovy and Ozempic side effects · GLP-1s and muscle loss · Menopause and weight gain · All weight and metabolism coverage
